42 related articles for article (PubMed ID: 32023488)
21. Enhanced oral delivery of hesperidin-loaded sulfobutylether-β-cyclodextrin/chitosan nanoparticles for augmenting its hypoglycemic activity: in vitro-in vivo assessment study.
Elmoghayer ME; Saleh NM; Abu Hashim II
Drug Deliv Transl Res; 2024 Apr; 14(4):895-917. PubMed ID: 37843733
[TBL] [Abstract][Full Text] [Related]
22. Application of Starch, Cellulose, and Their Derivatives in the Development of Microparticle Drug-Delivery Systems.
Lukova P; Katsarov P; Pilicheva B
Polymers (Basel); 2023 Aug; 15(17):. PubMed ID: 37688241
[TBL] [Abstract][Full Text] [Related]
23. Fabrication and Characterization of β-Cyclodextrin/
Liu HN; Jiang XX; Naeem A; Chen FC; Wang L; Liu YX; Li Z; Ming LS
Molecules; 2022 Dec; 28(1):. PubMed ID: 36615232
[TBL] [Abstract][Full Text] [Related]
24. Developed meloxicam loaded microparticles for colon targeted delivery: Statistical optimization, physicochemical characterization, and in-vivo toxicity study.
Wasay SA; Jan SU; Akhtar M; Noreen S; Gul R
PLoS One; 2022; 17(4):e0267306. PubMed ID: 35468155
[TBL] [Abstract][Full Text] [Related]
25. Circadian rhythms and cancers: the intrinsic links and therapeutic potentials.
Zhou L; Zhang Z; Nice E; Huang C; Zhang W; Tang Y
J Hematol Oncol; 2022 Mar; 15(1):21. PubMed ID: 35246220
[TBL] [Abstract][Full Text] [Related]
26. Utilization of Gelling Polymer to Formulate Nanoparticles Loaded with Epalrestat-Cyclodextrin Inclusion Complex: Formulation, Characterization, In-Silico Modelling and In-Vivo Toxicity Evaluation.
Alvi Z; Akhtar M; Rahman NU; Hosny KM; Sindi AM; Khan BA; Nazir I; Sadaquat H
Polymers (Basel); 2021 Dec; 13(24):. PubMed ID: 34960901
[TBL] [Abstract][Full Text] [Related]
27. Cyclodextrin-Modified Nanomaterials for Drug Delivery: Classification and Advances in Controlled Release and Bioavailability.
Real DA; Bolaños K; Priotti J; Yutronic N; Kogan MJ; Sierpe R; Donoso-González O
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959412
[TBL] [Abstract][Full Text] [Related]
28. Application of coating technology to chronotherapeutic drug delivery systems: Recent publications and patents.
Gowthami B; Krishna SVG; Rao DS
Curr Res Pharmacol Drug Discov; 2021; 2():100015. PubMed ID: 34909650
[TBL] [Abstract][Full Text] [Related]
29. Removing Control of Cyclodextrin-Drug Complexes Using High Affinity Molecule.
Kim YH; Kim ST; Jee JP; Kim DY; Kang D; Kim K; Park SY; Sim T; Cho KH; Jang DJ
J Nanosci Nanotechnol; 2018 Feb; 18(2):898-901. PubMed ID: 29448513
[TBL] [Abstract][Full Text] [Related]
30. Molecular simulation of hydroxypropyl-beta-cyclodextrin with hydrophobic selective Cox-II chemopreventive agent using host-guest phenomena.
Sinha VR; Nanda A; Chadha R; Goel H
Acta Pol Pharm; 2011; 68(4):585-92. PubMed ID: 21796941
[TBL] [Abstract][Full Text] [Related]
31. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles.
Liu Y; Sun C; Hao Y; Jiang T; Zheng L; Wang S
J Pharm Pharm Sci; 2010; 13(4):589-606. PubMed ID: 21486533
[TBL] [Abstract][Full Text] [Related]
32. Physicochemical characterization and in vitro dissolution behaviour of celecoxib-beta-cyclodextrin inclusion complexes.
Sinha VR; Anitha R; Ghosh S; Amita ; Kumria R; Bhinge JR; Kumar M
Acta Pharm; 2007 Mar; 57(1):47-60. PubMed ID: 19839406
[TBL] [Abstract][Full Text] [Related]
33. Formulation and development of extended-release micro particulate drug delivery system of solubilized rifaximin.
Karanje RV; Bhavsar YV; Jahagirdar KH; Bhise KS
AAPS PharmSciTech; 2013 Jun; 14(2):639-48. PubMed ID: 23516110
[TBL] [Abstract][Full Text] [Related]
34. Novel multiparticulate pH triggered delayed release chronotherapeutic drug delivery of celecoxib-β-cyclodextrin inclusion complexes by using Box-Behnken design.
Maqbool I; Akhtar M; Ahmad R; Sadaquat H; Noreen S; Batool A; Khan SU
Eur J Pharm Sci; 2020 Apr; 146():105254. PubMed ID: 32023488
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
